Insider has shown an interest in PHARMAC, New Zealands' medicine purse holder, since they had the sense not to take on COX 2's (unlike their nearest neighbour, Australia).
http://pharmagossip.blogspot.com/2005/10/coxibs-kiwis-beat-aussies.html
Here's what they are planning to spend on in the near future:
Drug /Investment type /Treats /5-year investment (NPV NZ$)
Adalimumab/ New medicine /Rheumatoid arthritis /$35 million
Alendronate/ Wider access/ Osteoporosis /$8.9 million
Gabapentin /Wider access /Pain relief /$18 million
Low-dose aspirin /New medicine/ Heart disease/ $17 million
Mycophenolate/ Wider access /Transplant rejection/ $8 million
Oxycodone/ New medicine/ Pain relief /$5 million
Pioglitazone /Wider access /Diabetes /$0.7 million
Ropinirole and entacapone /New medicines /Parkinsons Disease/ $2.4 million
Salmeterol /Wider access /Asthma/ $8 million
Total: a parsimonious NZ $103 million, over the next 5 years! Money well spent, in Insiders' view. Perhaps the breaking news on glitazones and macular oedema might lead to the pioglitazone decision being reviewed? But, other than that, a sensible use of resources!
http://www.scoop.co.nz/stories/GE0601/S00008.htm
No comments:
Post a Comment